Edgewise Therapeutics(EWTX) - 2023 Q4 - Annual Results

Exhibit 99.1 News Release Edgewise Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights – Overenrolled CANYON and advanced the global pivotal cohort, GRAND CANYON, of EDG-5506 in Becker muscular dystrophy (Becker) – – Advanced Phase 2 LYNX trial of EDG-5506 including new cohort for boys with Duchenne muscular dystrophy (Duchenne) not currently treated with corticosteroids – – Initiating Phase 2 FOX trial in boys with Duchenne who have been previously treate ...